These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 24713244)
1. [Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas]. Wang A; Lu L; Wang Y; Sun Y; Zhang Y; Guo C; Gu Y; Liu A Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):20-4. PubMed ID: 24713244 [TBL] [Abstract][Full Text] [Related]
2. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas]. Shen XX; Yu L; Bi R; Yang WT Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma]. Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529 [TBL] [Abstract][Full Text] [Related]
4. Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases. Concin N; Hefler L; van Bavel J; Mueller-Holzner E; Zeimet A; Daxenbichler G; Speiser P; Hacker N; Marth C Gynecol Oncol; 2003 Apr; 89(1):9-15. PubMed ID: 12694648 [TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer]. Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798 [TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
7. Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma. Roy M; Connor J; Al-Niaimi A; Rose SL; Mahajan A Hum Pathol; 2018 Mar; 73():1-6. PubMed ID: 28851663 [TBL] [Abstract][Full Text] [Related]
8. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma. Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277 [TBL] [Abstract][Full Text] [Related]
9. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma. Zhang J; Wang JC; Li YH; Wang RX; Fan XM Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510 [TBL] [Abstract][Full Text] [Related]
10. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma. Chen Y; Song J; Jiang Y; Yu C; Ma Z Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852 [TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832 [TBL] [Abstract][Full Text] [Related]
12. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454 [TBL] [Abstract][Full Text] [Related]
13. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma. Chen X; Wang X; Wei X; Wang J J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627 [TBL] [Abstract][Full Text] [Related]
14. Grading ovarian serous carcinoma using a two-tier system. Malpica A; Deavers MT; Lu K; Bodurka DC; Atkinson EN; Gershenson DM; Silva EG Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669 [TBL] [Abstract][Full Text] [Related]
15. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204 [TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of adhesive molecule CD44v6 in breast invasive ductal carcinoma]. Lian ZQ; Yang MT; Hou JH; Luo RZ; Wang X; Tang J Ai Zheng; 2006 Oct; 25(10):1291-5. PubMed ID: 17059779 [TBL] [Abstract][Full Text] [Related]
17. [Relationship between P53 Protein Expression and Prognosis of Advanced Ovarian Serous Adenocarcinoma]. Zuo J; Song Y; Li Z; Wu LY Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Apr; 38(2):169-74. PubMed ID: 27181893 [TBL] [Abstract][Full Text] [Related]
18. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence]. Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194 [TBL] [Abstract][Full Text] [Related]
19. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors]. Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316 [TBL] [Abstract][Full Text] [Related]
20. Glycodelin in ovarian serous carcinoma: association with differentiation and survival. Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]